Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

E Cortes

Showing results (431-440 of 584) with videos related to

Pageof 59
Sort By:
JAAD International|May 2, 2023
Teledermatology for skin cancer screening in rural Georgia utilizing teledermoscopy and distance learning: An ongoing reportMcKenzie E Maloney, Marisol Miranda-Galvis, Brenda Santellano Juarez, et al.
Leukemia Research|May 3, 2005
Adaptive randomized study of idarubicin and cytarabine alone or with interleukin-11 as induction therapy in patients aged 50 or above with acute myeloid leukemia or high-risk myelodysplastic syndromesFrancis J Giles, Hagop M Kantarjian, Jorge E Cortes, et al.
Transplantation and Cellular Therapy|October 5, 2020
Clinical Outcomes in Patients with FLT3-ITD-Mutated Relapsed/Refractory Acute Myelogenous Leukemia Undergoing Hematopoietic Stem Cell Transplantation after Quizartinib or Salvage Chemotherapy in the QuANTUM-R TrialSiddhartha Ganguly, Jorge E Cortes, Alwin Krämer, et al.
Cancer Medicine|October 16, 2018
A prospective analysis of symptom burden for patients with chronic myeloid leukemia in chronic phase treated with frontline second- and third-generation tyrosine kinase inhibitorsAlejandro Zulbaran-Rojas, Huei-Kan Lin, Qiuling Shi, et al.
Cancer Research|July 27, 2013
KIT signaling governs differential sensitivity of mature and primitive CML progenitors to tyrosine kinase inhibitorsAmie S Corbin, Thomas O'Hare, Zhimin Gu, et al.
Blood|April 2, 2014
Phase 2 trial of CPX-351, a fixed 5:1 molar ratio of cytarabine/daunorubicin, vs cytarabine/daunorubicin in older adults with untreated AMLJeffrey E Lancet, Jorge E Cortes, Donna E Hogge, et al.
Journal of Hematology & Oncology|July 16, 2020
Survival outcomes and clinical benefit in patients with acute myeloid leukemia treated with glasdegib and low-dose cytarabine according to response to therapyJorge E Cortes, Florian H Heidel, Walter Fiedler, et al.
British Journal of Haematology|April 3, 2004
Results of imatinib mesylate therapy in chronic myelogenous leukaemia with variant Philadelphia chromosomeMaha M T El-Zimaity, Hagop Kantarjian, Moshe Talpaz, et al.
American Journal of Hematology|May 13, 2016
Phase I study of evofosfamide, an investigational hypoxia-activated prodrug, in patients with advanced leukemiaTalha Badar, Damian R Handisides, Juliana M Benito, et al.
Blood Advances|March 20, 2019
Analysis of cardiovascular and arteriothrombotic adverse events in chronic-phase CML patients after frontline TKIsPreetesh Jain, Hagop Kantarjian, Prajwal C Boddu, et al.
Pageof 59

Showing results (431-440 of 584) with videos related to

Sort By:
Pageof 59
JAAD International|May 2, 2023
Teledermatology for skin cancer screening in rural Georgia utilizing teledermoscopy and distance learning: An ongoing reportMcKenzie E Maloney, Marisol Miranda-Galvis, Brenda Santellano Juarez, et al.
Leukemia Research|May 3, 2005
Adaptive randomized study of idarubicin and cytarabine alone or with interleukin-11 as induction therapy in patients aged 50 or above with acute myeloid leukemia or high-risk myelodysplastic syndromesFrancis J Giles, Hagop M Kantarjian, Jorge E Cortes, et al.
Transplantation and Cellular Therapy|October 5, 2020
Clinical Outcomes in Patients with FLT3-ITD-Mutated Relapsed/Refractory Acute Myelogenous Leukemia Undergoing Hematopoietic Stem Cell Transplantation after Quizartinib or Salvage Chemotherapy in the QuANTUM-R TrialSiddhartha Ganguly, Jorge E Cortes, Alwin Krämer, et al.
Cancer Medicine|October 16, 2018
A prospective analysis of symptom burden for patients with chronic myeloid leukemia in chronic phase treated with frontline second- and third-generation tyrosine kinase inhibitorsAlejandro Zulbaran-Rojas, Huei-Kan Lin, Qiuling Shi, et al.
Cancer Research|July 27, 2013
KIT signaling governs differential sensitivity of mature and primitive CML progenitors to tyrosine kinase inhibitorsAmie S Corbin, Thomas O'Hare, Zhimin Gu, et al.
Blood|April 2, 2014
Phase 2 trial of CPX-351, a fixed 5:1 molar ratio of cytarabine/daunorubicin, vs cytarabine/daunorubicin in older adults with untreated AMLJeffrey E Lancet, Jorge E Cortes, Donna E Hogge, et al.
Journal of Hematology & Oncology|July 16, 2020
Survival outcomes and clinical benefit in patients with acute myeloid leukemia treated with glasdegib and low-dose cytarabine according to response to therapyJorge E Cortes, Florian H Heidel, Walter Fiedler, et al.
British Journal of Haematology|April 3, 2004
Results of imatinib mesylate therapy in chronic myelogenous leukaemia with variant Philadelphia chromosomeMaha M T El-Zimaity, Hagop Kantarjian, Moshe Talpaz, et al.
American Journal of Hematology|May 13, 2016
Phase I study of evofosfamide, an investigational hypoxia-activated prodrug, in patients with advanced leukemiaTalha Badar, Damian R Handisides, Juliana M Benito, et al.
Blood Advances|March 20, 2019
Analysis of cardiovascular and arteriothrombotic adverse events in chronic-phase CML patients after frontline TKIsPreetesh Jain, Hagop Kantarjian, Prajwal C Boddu, et al.
Pageof 59